Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal meningitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi Pasteur

    • Most Recent Events

    • 23 Nov 2020 According to a Sanofi media release, based on the seven pivotal Phase 2 and 3 studies (NCT02955797, NCT03077438, NCT02199691, NCT02842866, NCT02752906, NCT02842853, NCT03205371), the European Commission (EC) has approved MenQuadfi for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
    • 22 Sep 2020 According to a Sanofi media release, Following this CHMP positive opinion, a final decision is anticipated by the end of this year. MenQuadfi is expected to be gradually available in Europe starting in 2021
    • 22 Sep 2020 According to a Sanofi media release, the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for MenQuadfi for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.The recommendation is supported by seven Phase 2 and 3 clinical studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top